PPP2R1A and neoplasm: Compared with treatment with LB100 or anti-PD1 alone, the combination of LB100 and anti-PD1 synergistically improved its activity on anti-tumour growth and increased survival (Fig. 5a), although the synergistic effect of LB100 and anti-PD1 was less than that of Ppp2r1a knockdown and anti-PD1 (Fig. 4c, e).